Message #26 From:
NewsBot Date: November 2, 2006 08:26:00 AM
SVNT News Savient Pharmaceuticals to Present at Rodman & Renshaw Eighth Annual Healthcare Conference
EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Savient Pharmaceuticals, Inc. (NASDAQ:SVNT), a biopharmaceutical company
focused on developing, manufacturing and marketing novel therapeutic
products for unmet medical needs, today announced that its Executive VP
and Chief Business Officer, Philip Yachmetz, will present at the
upcoming Rodman & Renshaw Eighth Annual Healthcare Conference. The
presentation is scheduled for 11:40 AM (Eastern Time) on Tuesday,
November 7, 2006. The event will be held from November 6-8, 2006 at the
New York Palace Hotel in New York.
Individuals may listen to a live web cast of the presentation by logging
on to the Investor Relations section of Savient Pharmaceuticals’
web site, www.savientpharma.com
a few minutes prior to start time to download any necessary software.
The conference will feature presentations from more than 290 public and
privately held emerging growth healthcare companies presenting data on
an array of therapeutic topics including oncology, cardiovascular
disease, central nervous system disorders, infectious diseases and
medical device technology. Details regarding the conference can be
obtained at www.rodmanandrenshaw.com.
About Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals is a biopharmaceutical company engaged in
developing, manufacturing and marketing pharmaceutical products that
target unmet medical needs in both niche and broader markets. The
Company's lead product development candidate, Puricase®
(PEG-uricase) for treatment failure gout, has reported positive Phase 1
and 2 clinical data; Phase 3 clinical studies began in May 2006.
Savient's experienced management team is committed to advancing its
pipeline and expanding its product portfolio by in-licensing late-stage
compounds and exploring co-promotion and co-development opportunities
that fit the Company's expertise in biopharmaceuticals with an initial
focus in rheumatology. Savient also markets Oxandrin®
(oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered
trademark of Mountain View Pharmaceuticals, Inc. Further information on
Savient can be accessed by visiting: www.savientpharma.com.
